Hypertension is a heart-related disease which results in elevated blood pressure in the arteries. It is also known as arterial hypertension or high blood pressure. This disease occurs on account of alcohol, smoking, obesity, and other genetic factors. Although, the disease can be treated with a healthy diet and exercise, antihypertensives are recommended to control it.
Antihypertensives are a class of drugs which can prevent hypertension and other cardiovascular-related disorders like strokes and myocardial infarction. They are likely to reduce the heart conditions by 21%. Beta blockers, thiazide diuretics, ACE inhibitors, calcium channel blockers, and angiotensin II receptor antagonists (ARBs) are the different types of antihypertensive therapeutics in major developed markets.
Read Complete Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries
Thiazide diuretics aid in reducing salt and water from the kidneys. They are the first drugs to be administered for a patient undergoing hypertension treatment. ACE inhibitors reduce serum creatinine levels better than beta blockers. They are considered the first line of defense against heart-related disorders. ARBs reduces the risko f myocardial infarction when combined with amlodipine. Beta blockers are considered risky and can lead to strokes or type-2 diabetes. However, they prevent heart attacks in persons who have already experienced a heart attack.
The hypertension market was estimated to have earned USD 40 billion of revenue in 2013. The market will attain USD 37 billion by 2020, owing to the patent expiry of major drugs. It is predicted to grow at a 2.6% CAGR during the period of 2014 to 2017. The market will experience growth on account of fixed-dose combination (FDCs) drugs, the rising geriatric population, and a low diagnosis rate.
Browse All Reports of This Category at: www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
FDCs include Amturnide, Azor, Twynsta, Exforge Tribenzor, Valturna, Benicar HCT, Tekturna HCT, Tekamlo, and Edarbyclor. New drugs in the pipeline are AHU377 + valsartan and azilsartan + amlodipine. Patients undergoing the treatment were known to have reduced levels of blood pressure. Drugs about to lose their patent are Exforge in 2014, Cozaar in 2010, Tekturna and Tekturna HCT in 2018, Benicar in 2016, and Atacand and Avapro in 2012.
The hypertension market has evolved from creating drugs to providing step-by-step special treatment dependent on the seriousness of the disease. The new classes of antihypertensive drugs are able to protect the kidneys, liver, heart, and brain from internal damage.
Explore Other Ongoing Reports By Radiant Insights, Inc at
- Acetic Acid Industry
About Radiant Insight
Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: Send Email
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States